# Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT00003620** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** alvocidib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00003620
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003620, "Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*